FilingSEC EDGAR6-K
Tiziana Life Sciences Signs MOU for Multiple Sclerosis Clinical Trial Collaboration
· SEC accepted
StageMOU Signed
Filing content
Tiziana signed an MOU with KAIMRC and other partners to collaborate on a clinical trial evaluating intranasal foralumab in combination with anti-CD20 therapy for multiple sclerosis.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…